Anti Wrinkle Clinic Limited iXBRL

Anti Wrinkle Clinic Limited

Director's Report and Unaudited Financial Statements

for the financial year ended 31 January 2025

Anti Wrinkle Clinic Limited

DIRECTOR AND OTHER INFORMATION


Director	Mr Ioannis Valilas


Company Registration Number	11764007


Registered Office and Business Address	13 Rosler Building 85 Ewer Street
	London
	London
	SE1 0FT
	United Kingdom


Accountants	JLK Associates Limited
	145
	Junction Road
	London
	N19 5PX
	United Kingdom

Anti Wrinkle Clinic Limited

DIRECTOR'S REPORT

for the financial year ended 31 January 2025

The director presents their report and the unaudited financial statements for the financial year ended 31 January 2025.

Director

The director who served during the financial year is as follows:

Mr Ioannis Valilas

There were no changes in shareholdings between 31 January 2025 and the date of signing the financial statements.

In accordance with the Constitution, the director retire by rotation and, being eligible, offer themselves for re-election.

Political Contributions

The company did not make any disclosable political donations in the current financial year.

Statement of Director's Responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A (Small Entities). Under company law the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the director is required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Special provisions relating to small companies

The above report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

On behalf of the board

___________________________

Mr Ioannis Valilas

Director

6 October 2025

Anti Wrinkle Clinic Limited

ACCOUNTANTS REPORT

to the Director on the Compilation of the unaudited financial statements of Anti Wrinkle Clinic Limited

for the financial year ended 31 January 2025

In accordance with the engagement letter and in order to assist you to fulfil your duties under the Companies Act 2006, we have compiled for your approval the financial statements of the company for the financial year ended 31 January 2025 as set out on pages 6 to 13 which comprise the Profit and Loss Account, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given to us.

This report is made solely to the director of Anti Wrinkle Clinic Limited, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company’s Director that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and its director for our work or for this report.

We have carried out this engagement in accordance with guidance issued by and have complied with the relevant ethical guidance laid down by relating to members undertaking the compilation of financial statements.

You have acknowledged on the Balance Sheet for the year ended 31 January 2025 your duty to ensure that Anti Wrinkle Clinic Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Anti Wrinkle Clinic Limited. You consider that Anti Wrinkle Clinic Limited is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the financial statements of Anti Wrinkle Clinic Limited. For this reason, we have not verified the adequacy, accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

__________________________________

JLK ASSOCIATES LIMITED

145

Junction Road

London

N19 5PX

United Kingdom

6 October 2025

Anti Wrinkle Clinic Limited

PROFIT AND LOSS ACCOUNT

for the financial year ended 31 January 2025

	2025	2024
Notes	£	£

Turnover	346,598	272,532

Cost of sales	(110,746)	(91,860)
	─────────	─────────
Gross profit	235,852	180,672

Administrative expenses	(201,560)	(141,383)
	─────────	─────────
Profit on ordinary activities before taxation	34,292	39,289

Tax on profit on ordinary activities	(6,903)	(6,402)
	─────────	─────────
Profit for the financial year	27,389	32,887
	─────────	─────────
Total comprehensive income	27,389	32,887
	═════════	═════════

Anti Wrinkle Clinic Limited

Company Registration Number: 11764007

BALANCE SHEET

as at 31 January 2025

		2025	2024
	Notes	£	£

Fixed Assets

Intangible assets

1,399

1,706

─────────

Current Assets

Stocks

5,628

857

Debtors

1,266

1,147

Cash and cash equivalents

8,942

─────────

15,836

2,004

─────────

Creditors: amounts falling due within one year

(13,058)

(145)

─────────

Net Current Assets

2,778

1,859

─────────

Total Assets less Current Liabilities

4,177

3,565

═════════

Capital and Reserves

Called up share capital

Retained earnings

4,176

3,564

─────────

Equity attributable to owners of the company

4,177

3,565

═════════

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).

For the financial year ended 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The director confirms that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Approved by the Director and authorised for issue on 6 October 2025



________________________________
Mr Ioannis Valilas
Director

Anti Wrinkle Clinic Limited

STATEMENT OF CHANGES IN EQUITY

as at 31 January 2025

	Called up	Retained	Total
	share	earnings
	capital
	£	£	£

At 1 February 2023	-	(1,207)	(1,207)
	─────────	─────────	─────────
Profit for the financial year	-	32,887	32,887
	─────────	─────────	─────────
Payment of dividends	-	(28,116)	(28,116)
	─────────	─────────	─────────
At 31 January 2024	1	3,564	3,565
	─────────	─────────	─────────
Profit for the financial year	-	27,389	27,389
	─────────	─────────	─────────
Payment of dividends	-	(26,777)	(26,777)
	─────────	─────────	─────────
At 31 January 2025	1	4,176	4,177
	═════════	═════════	═════════

Anti Wrinkle Clinic Limited

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 January 2025

General Information

Anti Wrinkle Clinic Limited is a company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 11764007. The registered office of the company is 13 Rosler Building 85 Ewer Street, London, London, SE1 0FT, United Kingdom which is also the principal place of business of the company. Dental practice activities The financial statements have been presented in Pound (£) which is also the functional currency of the company.

Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 January 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Intangible assets

Intangible assets are valued at cost less accumulated amortisation.

Amortisation is calculated to write off the cost in equal annual instalments over their estimated useful life of 0 years.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Research and development

Development expenditure is written off in the same financial year unless the director are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period from which the company is expected to benefit.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

Employees

The average monthly number of employees, including director, during the financial year was 2, (2024 - 1).

2025

2024

Number

Number

Employees

═════════


4.	Intangible assets
		Development
		Costs	Total
		£	£
	Cost
	At 1 February 2024	3,710	3,710
		─────────	─────────

	At 31 January 2025	3,710	3,710
		─────────	─────────
	Amortisation
	At 1 February 2024	2,004	2,004
	Charge for financial year	307	307
		─────────	─────────
	At 31 January 2025	2,311	2,311
		─────────	─────────
	Net book value
	At 31 January 2025	1,399	1,399
		═════════	═════════
	At 31 January 2024	1,706	1,706
		═════════	═════════


5.	Stocks	2025	2024
		£	£

	Finished goods and goods for resale	5,628	857
		═════════	═════════

	The replacement cost of stock did not differ significantly from the figures shown.


6.	Debtors	2025	2024
		£	£

	Trade debtors	978	1,000
	Other debtors	288	-
	Taxation (Note 8)	-	147
		─────────	─────────
		1,266	1,147
		═════════	═════════


7.	Creditors	2025	2024
	Amounts falling due within one year	£	£

	Bank overdrafts	4,113	(7,007)
	Taxation (Note 8)	8,195	6,402
	Accruals	750	750
		─────────	─────────
		13,058	145
		═════════	═════════


8.	Taxation	2025	2024
		£	£

	Debtors:
	VAT	-	147
		═════════	═════════
	Creditors:
	VAT	1,292	-
	Corporation tax	6,903	6,402
		─────────	─────────
		8,195	6,402
		═════════	═════════


9.	Share capital			2025	2024
				£	£
	Description	Number of shares	Value of units

	Allotted, called up and fully paid
	Ordinary	1	£1.00 each	1	1

				═════════	═════════

10.

Capital commitments

The company had no material capital commitments at the financial year-ended 31 January 2025.

11.

Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.